Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Clinical Study on Dose Escalation Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Dose of AK139 in Healthy Subjects

Next Previous
Trial Profile

A Phase I Clinical Study on Dose Escalation Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Dose of AK139 in Healthy Subjects

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 05 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AK 139 (Primary)
  • Indications Respiratory tract disorders; Skin disorders
  • Focus Adverse reactions
  • Sponsors Akeso Biopharma

Most Recent Events

  • 27 Apr 2025 Status changed from planning to not yet recruiting.
  • 21 Feb 2025 New trial record
  • 13 Feb 2025 According to Akeso, Inc., media release, the company announced the acceptance of its Investigational New Drug (IND) application by the China National Medical Products Administration (NMPA) for AK139

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top